The NHS has approved Casgevy, a groundbreaking gene-editing treatment for sickle cell disease, offering hope to thousands. Expected to help 50 patients annually, the £1.65 million therapy corrects faulty genes, significantly reducing hospital visits. The treatment will be available at NHS...
Image Credit: NHLBI
In a historic move, the Food and Drug Administration (FDA) has granted approval for Casgevy, a powerful treatment for sickle cell disease, affecting over 100,000 Americans, primarily from the Black community.
Developed by Vertex Pharmaceuticals and CRISPR Therapeutics, this...
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.